Thus, this study evaluated whether kratom extracts and the major constituent mitragynine could inhibit the enzymatic activities of α-glucosidase and pancreatic lipase, which are two of the most common molecular targets of anti-diabetic agents (i.e., acarbose) and anti-obesity agents (i.e., orlistat), respectively [5,6,7]. The gene discussed is PNLIP; the disease is Obesity.